Phase i study of enzastaurin and bevacizumab in patients with advanced cancer: Safety, efficacy and pharmacokinetics

Nwabundo Nwankwo, Zhe Zhang, Ting Wang, Connie Collins, Lee Resta, Sabine Ermisch, Jeannette Day, Rodney Decker, Lori Kornberg, Steven Nicol, Donald Thornton, Deborah K. Armstrong, Michael A. Carducci

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Purpose Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination's safety and efficacy. Patients and methods Six advanced cancer patients could be enrolled in each of 11 cohorts. Patients received an enzastaurin loading dose. Oral enzastaurin (500 mg once daily [QD], 250 mg twice daily [BID], 375 mg BID, 500 mg BID, and 750 mg BID) was escalated in each cohort in combination with bevacizumab dosed at 5 mg/kg every 2 weeks, 10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks until a dose-limiting toxicity (DLT) occurred in 2 of 6 patients in any cohort. Results Sixty-seven patients (31, ovarian cancer [ovcar]) were evaluable for safety and efficacy. Six treatment-related DLTs occurred: grade 3 fatigue (n = 4), grade 4 cerebral hemorrhage, and grade 3 elevated aspartate transaminase. Common drug-related toxicities included change in color of urine and stool, fatigue, pain, diarrhea, and nausea. The maximum tolerated dose of enzastaurin was 750 mg BID in combination with any tested bevacizumab dose/schedule. Overall response rate was 19.4 % (32.3 % ovcar). Median time to progression was 3.7 months (95 % confidence interval [CI], 2.7-5.5), with 8.3 months (95 % CI, 3.7-11.1) in ovcar. Overall, 35.9 % (50.4 % ovcar) of patients remained without disease progression after 6 months. Conclusion The recommended phase II doses of enzastaurin were 500 mg QD up to 500 mg BID with any tested dose/schedule of bevacizumab. This combination demonstrated encouraging clinical activity, particularly in ovcar.

Original languageEnglish (US)
Pages (from-to)653-660
Number of pages8
JournalInvestigational New Drugs
Issue number3
StatePublished - Jun 2013


  • Advanced cancer
  • Bevacizumab
  • Enzastaurin
  • Ovarian cancer
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase i study of enzastaurin and bevacizumab in patients with advanced cancer: Safety, efficacy and pharmacokinetics'. Together they form a unique fingerprint.

Cite this